ID

13808

Descripción

Decitabine and Plerixafor in Elderly Acute Myeloid Leukemia (AML); ODM derived from: https://clinicaltrials.gov/show/NCT01352650

Link

https://clinicaltrials.gov/show/NCT01352650

Palabras clave

Versiones (1)
  1. 7/3/16 7/3/16 -
Titular de derechos de autor

CC BY-NC 3.0

Subido en

7 de marzo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY-NC 3.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Acute Myeloid Leukemia NCT01352650

Inglés

Eligibility Acute Myeloid Leukemia NCT01352650

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
unequivocal pathologic diagnosis of aml (≥ 20% blasts in the bone marrow based on who criteria) excluding: i) acute promyelocytic leukemia t(15;17)(q22;q12); pml-rara; ii)acute myeloid leukemia with t(8;21)(q22;q22); runx1-runxt1; iii) acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); cbfb-myh11.
Descripción

AML

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2]
C0023487
aml patients with an antecedent hematologic disorder or myelodysplastic syndrome (mds)are eligible for treatment on this trial provided that they have not received prior treatment with decitabine or prior cytotoxic treatment for aml.
Descripción

AML

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023467
UMLS CUI [2,1]
C3463824
UMLS CUI [2,2]
C0332152
UMLS CUI [3]
C0049065
aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for >6 months.
Descripción

therapy-related myeloid neoplasms

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2939461
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C2924519
UMLS CUI [2]
C0392920
age ≥ 60 years.
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
ability to understand and willingness to sign a written informed consent document.
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior treatment with decitabine
Descripción

prior treatment with decitabine

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0049065
UMLS CUI [1,2]
C1514463
prior treatment with plerixafor
Descripción

prior treatment with plerixafor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1955474
UMLS CUI [1,2]
C1514463
ongoing treatment for another malignancy.
Descripción

concurrent therapy for another malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0006826
UMLS CUI [1,2]
C0087111
UMLS CUI [1,3]
C0205420
patients with good-risk molecular or cytogenetics features
Descripción

molecular or cytogenetics features

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0010802
UMLS CUI [2]
C1521991
patient has a medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment.
Descripción

comorbidity limiting study protocol

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2348563
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
Descripción

comorbidity limiting consent and completion

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0021430
UMLS CUI [1,2]
C0439801
UMLS CUI [1,3]
C0009488
patient has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements.
Descripción

compliance behaviour

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1321605
Volver a la parte superior de la página

Similar models

Eligibility Acute Myeloid Leukemia NCT01352650

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
AML
Item
unequivocal pathologic diagnosis of aml (≥ 20% blasts in the bone marrow based on who criteria) excluding: i) acute promyelocytic leukemia t(15;17)(q22;q12); pml-rara; ii)acute myeloid leukemia with t(8;21)(q22;q22); runx1-runxt1; iii) acute myeloid leukemia with inv(16)(p13.1;q22) or t(16;16)(p13.1;q22); cbfb-myh11.
boolean
C0023467 (UMLS CUI [1])
C0023487 (UMLS CUI [2])
AML
Item
aml patients with an antecedent hematologic disorder or myelodysplastic syndrome (mds)are eligible for treatment on this trial provided that they have not received prior treatment with decitabine or prior cytotoxic treatment for aml.
boolean
C0023467 (UMLS CUI [1])
C3463824 (UMLS CUI [2,1])
C0332152 (UMLS CUI [2,2])
C0049065 (UMLS CUI [3])
therapy-related myeloid neoplasms
Item
aml patients with therapy-related myeloid neoplasms (t-mn) are eligible if they have not received chemotherapy (not including hormonal therapy) for their primary malignancy or disorder for >6 months.
boolean
C2939461 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C2924519 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
age
Item
age ≥ 60 years.
boolean
C0001779 (UMLS CUI [1])
informed consent
Item
ability to understand and willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
prior treatment with decitabine
Item
prior treatment with decitabine
boolean
C0049065 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
prior treatment with plerixafor
Item
prior treatment with plerixafor
boolean
C1955474 (UMLS CUI [1,1])
C1514463 (UMLS CUI [1,2])
concurrent therapy for another malignancy
Item
ongoing treatment for another malignancy.
boolean
C0006826 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C0205420 (UMLS CUI [1,3])
molecular or cytogenetics features
Item
patients with good-risk molecular or cytogenetics features
boolean
C0010802 (UMLS CUI [1])
C1521991 (UMLS CUI [2])
comorbidity limiting study protocol
Item
patient has a medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational drug treatment.
boolean
C2348563 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
comorbidity limiting consent and completion
Item
patient has a psychiatric disorder or altered mental status that would preclude understanding of the informed consent process and/or completion of the necessary studies.
boolean
C0021430 (UMLS CUI [1,1])
C0439801 (UMLS CUI [1,2])
C0009488 (UMLS CUI [1,3])
compliance behaviour
Item
patient has an inability or unwillingness, in the opinion of the investigator, to comply with the protocol requirements.
boolean
C1321605 (UMLS CUI [1])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial